Tharimmune to Present at 2024 BIO International Convention
Tharimmune, a clinical-stage biotech firm specializing in inflammation and immunology therapies, will present at the 2024 BIO International Convention from June 3-6 in San Diego. The company will showcase its therapeutic candidates and hold one-on-one meetings with investors and industry leaders. The presentation is scheduled for June 3 at 1:45 p.m. PT in Company Presentation Theater 3. Interested parties can arrange meetings via the BIO One-on-One Partnering system or by contacting Tirth Patel of LHA Investor Relations.
- Tharimmune's participation in the 2024 BIO International Convention could increase visibility and attract investors.
- Presentation scheduled at a prominent industry event signals active engagement with the biotech community.
- Opportunity for one-on-one meetings with potential investors and industry leaders could lead to new partnerships.
- No new financial data or clinical results were mentioned, leaving investors without updates on performance or progress.
- The announcement focuses on the event rather than substantive business advancements or milestones.
BRIDGEWATER, NJ / ACCESSWIRE / May 29, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego.
The Company will be presenting at the convention and will hold 1x1 meetings with investors and industry leaders.
Event: | 2024 BIO International Convention |
Date: | Monday, June 3, 2024 |
Time: | 1:45 p.m. Pacific Time |
Location: | Company Presentation Theater 3 |
To schedule a meeting with the Company's management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact Tirth Patel from LHA Investor Relations at tpatel@lhai.com.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company's lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The Company's early-stage immunology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors, including PD-1, HER2 and HER3. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against these and other specified targets. For more information please visit: www.tharimmune.com.
Contacts:
Tharimmune, Inc.
ir@tharimmune.com
LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614
SOURCE: Tharimmune, Inc.
View the original press release on accesswire.com
FAQ
What does Tharimmune do?
When is Tharimmune presenting at the 2024 BIO International Convention?
Where is the 2024 BIO International Convention being held?
How can I schedule a meeting with Tharimmune at the BIO Convention?
